Neil Davie

R&D

What do 300 million people have in common? They are living with rare diseases that are defined by their scarcity within the general population.

Oncology

Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.